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THE FUTURE OF CANNABIS MANUFACTURING
IN GEORGIA
Ever since Georgia legalized non-smokable forms of medical cannabis in
2015, the question of how to provide qualified patients with safe access to legally
permitted products has vexed the legislature. 1 This quandary led to the formation
of not one but two legislative commissions to investigate the dilemma and
provide recommendations. 2 The first of these was the Georgia Commission on
Medical Marijuana. 3 Although its efforts at legislation were ultimately
unsuccessful4, its validation of the problem precipitated creation of a second,
more-focused commission, the Joint Study Commission on Low-THC Medical
Oil Access. After eight months of hearings and comparative state law analysis,
that commission released its final report in December of 2018. 5
The report’s two-page “Findings and Recommendations” first urges the
federal government to reschedule cannabis from a Schedule I drug to a Schedule
II drug. 6 Rescheduling cannabis as a less restricted drug would open up new
options for publically-funded research and distribution, options not currently
being considered because of federal funding implications. 7 The Commission
goes on to state, however, “in the event the federal government fails to
[reschedule cannabis], the Commission recommends that the General Assembly
pass legislation during the 2019 Legislative Session” pertaining to “the security
and control of all aspects of the [cannabis cultivation] process” and “quality

1
See Greg Bluestein, Governor Signs Bill Making Medical Marijuana Legal in Georgia, Atlanta Journal
Constitution (updated April 16, 2015) https://www.ajc.com/news/state—regional-govt—politics/governorsigns-bill-making-medical-marijuana-legal-georgia/KHsJFH2sU5WPOIOoPqmXyK/, and Kristen Torres,
Georgia Lawmaker Re-Ups Plea for Cultivation of Medical Marijuana, Atlanta Journal Constitution (Sept. 28,
2017) https://www.ajc.com/news/state—regional-govt—politics/georgia-lawmaker-ups-plea-for-cultivationmedical-marijuana/0F3FEq2mzdRL183WjHLaHM/.
2
See H.B. 1, 153rd Gen. Assemb., Reg. Sess. (Ga 2015), and H.B. 65, 154th Gen. Assemb., Reg. Sess.
(Ga. 2017).
3
See Aaron Gould Sheinin, Deal Names Peake to Lead Medical Marijuana Commission, Atlanta Journal
Constitution (updated May 18, 2015) https://www.ajc.com/news/state—regional-govt—politics/deal-namespeake-lead-medical-marijuana-commission/kiJ37a6U6I8vGl9OuOS0aN/.
4
See Kristen Torres, Push to Expand Georgia’s Medical Marijuana Law Has Stalled in Senate, Atlanta
Journal Constitution (Mar. 14, 2016), https://www.ajc.com/news/state—regional-govt—politics/medicalmarijuana-push-criticized-georgia-prosecutors/i8gS2HEDDWoAZaFjYlHy5J/.
5
Senate Research Office and House Budget and Research Office, Final Report of the Joint Commission
on Low THC Medical Oil Access (December 2018) http://www.house.ga.gov/Documents/
CommitteeDocuments/2018/Low_THC_Medical_Oil_Access/Joint_Commission_on_Low_THC_Final_Repor
t_2018.pdf.
6
Id. pg. 5
7
See Associated Press, Georgia Lawmakers Back Legalizing Medical Marijuana, Fox News (Mar. 4,
2014) https://www.foxnews.com/politics/georgia-lawmakers-back-legalizing-medical-marijuana.
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control.” 8 Although the short report provides little guidance in terms of creating
an effective regulatory framework, it clearly calls for the creation of a
comprehensive regime to regulate the domestic cultivation and distribution of
cannabis in Georgia. 9
Detailed regulations backed by severe penalties for manufacturers’
noncompliance will be necessary to secure passage of any proposal though. 10 To
better protect their clients, attorneys interested in advising applicants will need
to anticipate the regulatory framework likely to become law. Those looking to
predict the shape of that framework must consider the commission’s brief report
in the context of prior legislative history, which provides some guidance on how
the legislature might handle key challenges not adequately addressed by the
report. By examining the Commission’s report alongside previous proposals, we
can gain a better idea of the considerations likely to guide future regulations,
particularly those pertaining to the local cultivation and distribution of cannabis,
and can make more accurate predictions about the future of cannabis
manufacturing in Georgia.
Georgia’s first steps on the journey to the in-state production of cannabis
began with the enactment of House Bill 1 in 2015. 11 Indicative of its
compassionate intent, the bill was coined “Haleigh’s Hope Act” in honor of
Haleigh Cox, a child who suffers from epilepsy but is able to manage her
debilitating disease through the use of medical cannabis oil. 12 Although the law
allows compassionate use, it does not provide any means for qualified citizens
to access their physician prescribed medication without traveling outside the
state. 13 As a consequence, patients like Haleigh have been forced to cross state
lines with their medicine, breaking both state and federal drug trafficking laws
in the process. 14 Since that original legislation, the list of covered diseases has
been expanded from eight to sixteen ailments, 15 but there has been little progress
towards resolving the in-state access dilemma. In fact, Georgia’s House of
Representatives rejected the only proposal submitted for a vote to date, House

8

See Final Report of the Joint Commission on Low THC Medical Oil Access supra at 5-6.
See generally Id.
10
Torres, supra note 4.
11
Bluestein, supra note 1.
12
See Lauren Sennet, Girl’s Seizures Spur Medical Marijuana Legislation in Georgia, CNN (April 16,
2015)
https://www.cnn.com/2015/04/16/us/georgia-medical-marijuana-bill-signing-haleigh-cox/index.html;
See also Haleigh’s Hope website, http://haleighshope.co/meet-haleigh/.
13
See Bluestein, supra note 1.
14
See Correction: Medical Marijuana Story, U.S. News (Feb. 14, 2018, 3:54 pm), https://www.usnews.
com/news/best-states/georgia/articles/2018-02-13/gov-deal-opposes-medical-marijuana-cultivation-in-georgia.
15
See H.B. 65.
9
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Bill 722 (“H.B. 722”). Although this bill did not ultimately pass, much can be
learned about the considerations likely to guide future legislation relevant to the
manufacture and distribution of cannabis in Georgia by examining that proposal.
The following list of measures relate to supply chain concerns associated with
in-state manufacturing and are most likely to steer the legislative debate.
First, despite a disjunctive definition of “manufacturer,” 16 H.B. 722 would
have obligated each license holder to house all “cultivation, harvesting,
manufacturing, packaging, and processing” at a single facility from which
products would be shipped to their dispensary locations. 17 Such a requirement
forces manufacturers to be vertically integrated, and thus able to bring products
to market single-handedly, increasing product control and the risks associated
with transfer and mishandling. This vision of vertical integration was supported
by the commission in the lead up to its report. 18 If the legislature agrees with
their assessment, it will likely require potential manufacturers demonstrate this
structural capability before obtaining a license.
Second, as part of the licensing process, H.B. 722 would have required
manufacturers of cannabis to demonstrate the ability to meet strict due dates for
commencement of operations 19 and pay a non-refundable fee of $20,000.00. 20
These requirements work to front-load much of the expense of starting a
manufacturing operation. Front-loading acts as a safeguard, relying on banking
and zoning laws to ensure only legitimate business interests with strong
community ties are able to secure the significant upfront investment and local
support needed to obtain a license. The Commission similarly recommended a
“one-year deadline for commencement of operations” and “[user] application
and licensing fees.” 21 Although the commencement timeframe and fee amount
is subject to adjustment, the legislature is likely to employ similar requirements
in keeping with this front-loading theory.
Third, H.B.722 would have obliged the state to “register a minimum of two
and a maximum of six in-state manufacturers” 22 with each registered

16
See H.B. 722, 153rd Gen. Assemb., Reg. Sess. (Ga. 2016) at 31-2B-1(6); “Manufacturer,” is defined
as any registered entity allowed to “cultivate, acquire, manufacture, possess, prepare, transfer, transport, supply
or dispense medical cannabis, delivery devices or related supplies and educational materials.”
17
Id. at 31-2B-12(A).
18
See Susan Driscoll, Joint Study Commission on Low THC Medical Cannibis Oil Access (Sept., 18,
2018) http://www.senate.ga.gov/committees/Documents/LowTHC_Susan_Driscoll9-18-18.pdf.
19
Id. at 31-2B-4(B)(1).
20
See H.B. 722 at 31-2B-20(B).
21
See Final Report of the Joint Commission on Low THC Medical Oil Access at 5-6.
22
See H.B. 722 at 31-2B-4(C)(1-6).
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manufacturer limited to the operation of four “distribution facilities, . . . based
on geographical need throughout the state.” 23 Such limitations on available
licenses and consumer-facing dispensaries corral what would otherwise likely
be a proliferation in cannabis dispensaries across the state. The Commission’s
report was notably different, however, suggesting the state offer “ten grow
licenses, ten manufacturing licenses, and an adequate number of dispensing
licenses.” 24 Considering its previous endorsement of a vertically integrated
business model, it is curious that the commission did not explicitly dictate
licensed manufacturers also be licensed growers and dispensers; however, the
more interesting takeaways are the opinions of the commission that more
licenses are needed than previously suggested and the number of dispensaries
should be left to some discretion based on evolving needs. While compromise is
sure to play a role in this determination, the legislature will undoubtedly include
similar limits as a means of lessening opportunities for errant cannabis to
become available outside the regulated market.
While limitations on the number of facilities reduces the risk of unaccounted
for cannabis on a macro level, facility security measures and integrated tracking
systems perform a similar function at the micro level. Under H.B. 722, not only
would manufacturers have had to implement certain basic facility security
measures, 25 but they would have also had to track all processed products 26 and
submit monthly reports to the Commissioner with detailed distribution data. 27
Although the Commission’s report does not mention security or tracking
systems, future participants can be sure the legislature will require
manufacturers take reasonable security precautions and maintain detailed
records for state inspection along every stage of the manufacture and distribution
process.
Fourth, in addition to these product control measures, H.B. 722 included
provisions aimed at ensuring product safety, potency, and legitimacy.
Manufacturers would have been subject to “reasonable [State] inspection,” at
the behest of the Commissioner , 28 including “independent laboratory testing” 29
of product “content, contamination, and consistency,” 30 and “examinations of

23
24
25
26
27
28
29
30

Id. at 31-2B-12(A).
See Final Report of the Joint Commission on Low THC Medical Oil Access at 5-6.
See H.B. 722, 153rd Gen. Assemb., Reg. Sess. (Ga. 2016) at 31-2B-12(D).
Id. at 31-2B-5.1(D)(17)(E).
Id. at 31-2B-13(H)(1-3).
Id. at 31-2B-12(G).
Id. at 31-2B-4(D).
Id. at 31-2B-12(B).
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the business’s affairs and conditions.” 31 These extensive inspection powers with
no notice requirement may have in and of themselves been sufficient to assure
regulatory compliance, but for good measure, H.B. 722 would have also
assessed an annual user fee “equal to the cost of regulating and inspecting” a
manufacturer’s operations. 32 Assigning these costs to manufacturers would have
created an even stronger incentive to comply as a means of reducing associated
fees. Similarly, the Commission suggests “independent lab testing procedures
with minimum standards for product purity and safety.” 33 While it provides no
further detail regarding actual testing procedures, the Commission previously
floated the idea of utilizing those used by the state’s Board of Pharmacy. 34
Whether the legislature chooses to utilize the inspection and product testing
procedures set forth in H.B. 722, those of the Board of Pharmacy as opined by
the Commission or its own newly created set, there will almost certainly be some
prescription for inspection and testing to ensure quality control.
Fifth, in addition to the prior operational requirements, H.B. 722 dictated the
manner in which manufacturers would have advertised and sold their products.
For instance, “signage, marketing, display and advertising,” 35 as well as “patient
fees,” 36 would have been subject to reasonable restriction. Manufacturers would
also have been prevented from employing anyone under the age of twenty-one
or with a criminal background. 37 Perhaps most importantly though,
manufacturers would only have been able to sell their products to patients
registered with the state. 38 Punishment for violations of these restrictions would
have included up to two years imprisonment, 39 up to $3,000.00 in fines, 40
permanent debarment, 41 and “any other applicable penalties in law.” 42 By
holding manufacturers liable for violations of these point-of-sale restrictions,
such policies encourage manufacturers to make prudent decisions regarding how
they sell products with the ultimate goal of limiting cannabis use to medicinal,
rather than recreational, purposes. The commission’s report does not specify
similar restrictions or penalties, although it does allude to heavy state oversight
31
32
33
34
35
36
37
38
39
40
41
42

Id. at 31-2B-5(D-G).
Id. at 31-2B-20(C).
See Final Report of the Joint Commission on Low THC Medical Oil Access at 5-6.
See Driscoll, supra note 18.
See H.B. 722, 153rd Gen. Assemb., Reg. Sess. (Ga. 2016) at 31-2B-12(K).
Id. at 31-2B-20(D).
Id. at 31-2B-12(I).
Id. at 31-2B-13(F) (1-6).
Id. at 31-2B-18(A).
Id. at 31-2B-18(A).
Id. at 31-2B-18(A).
Id. at 31-2B-18(F).
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by both the Georgia Department of Public Health and the Georgia Bureau of
Investigations. 43 Considering the state’s aversion to facilitating the recreational
use of cannabis, it is likely the legislature will create similar restrictions,
although with perhaps more detailed parameters, and enhanced penalties so as
to further deter violations.
Lastly, H.B. 722 would have charged the Georgia Commission on Medical
Marijuana with several regulatory tasks. 44 This state agency would have been
entrusted with licensing authority, based on the evaluation of six prescribed
criteria including technical expertise, employee qualifications, financial
stability, security, capability and projected patient-fee assessment. 45 The agency
would have had to create and maintain a “patient registry program” 46 to limit
access to only those citizens with “qualifying medical conditions.” 47 It would
also be charged with oversight, inspection and enforcement duties to ensure
manufacturer compliance. Additionally, H.B. 722 called for creation of a “task
force” consisting of twenty specifically designated members to conduct “an
impact assessment on the use of medical cannabis” and suggest appropriate
modifications if necessary. 48 Taken as whole, these safeguards would have given
the State an unfettered ability to exert regulatory authority at each stage of the
distribution process, from cultivation to consumption. Similarly, the
Commission’s report suggests the duty of licensing be a state function, however,
the only parameter it provides is that “half of the licenses [be] granted to large
capital investment entities, and half to smaller capital investment entities.” 49 It
also mentions a state-run patient registry like H.B. 722 but it did not go so far as
to suggest any post-implementation assessments. 50 Depending on the extent to
which the legislature allows for discretionary determinations, the responsibilities
placed on the state’s regulatory body may be expanded or even narrowed from
that proposed in H.B. 722, but regardless, the state will undoubtedly retain the
exclusive ability to grant licenses and control the registration of qualified
patients.
Despite H.B. 722’s inability to garner the requisite support to become law,
it certainly presents a starting point for anticipating the framework likely to

43
44
45
46
47
48
49
50

See Final Report of the Joint Commission on Low THC Medical Oil Access at 5-6.
See generally H.B. 722.
Id. at 31-2B-4(C)(1-6).
Id. at 31-2B-8(A).
Id. at 31-2B-1(11).
Id. at 31-2B-21; 31-2B-22.
See Final Report of the Joint Commission on Low THC Medical Oil Access at 5-6.
Id. at 5-6.
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regulate the manufacturing of cannabis in the state. Because of its apparent
inadequacy though, it would be prudent to consider the criticisms leveled against
it. For instance, Senate Health and Human Services Chairwoman Renee
Unterman was reported as generally feeling it “needed more work and
discussion.” 51 More pointedly, the Executive Director of the Prosecuting
Attorneys’ Council of Georgia, Chuck Spanos, criticized it for assigning product
tracking duties to manufacturers with purely profit-driven objectives. 52
Considering the end result will have to include some means for qualified patients
to access cannabis without leaving the state, the legislature may find it difficult
to strike the right balance for a historically conservative state whose leadership
has openly expressed a strong aversion to any law expanding access. 53 It will
likely need to propose a more tightly regulated program than that of H.B. 722 in
order to become law, but thankfully, there are ways to achieve this goal without
completely discarding the foundation laid in H.B. 722.
In response to general concerns, the legislature may decide to strengthen the
State’s enforcement capabilities. It could provide the State with additional
enforcement tools such as injunction, seizure and condemnation provisions, and
concomitantly increase H.B. 722’s modest provisions for criminal prosecution
and civil money penalties to enhance their deterrence factor. The legislature
could also require outside compliance consultants to be on-site and
independently liable for code violations, presumably at a premium cost to
manufacturers akin to insurance. By augmenting the state’s ability to constrain
and penalize manufacturers, general concerns regarding the law’s efficacy
should be sufficiently assuaged.
Further, regarding Mr. Spanos’ concern that “the fox is guarding the
henhouse” 54, perhaps the legislature could further explore limiting licenses to
non-profit organizations. This essentially cosmetic fix may entail state-funded
subsidies for start-up costs and reasonable allowances to cover operational
expenses, but this trade-off could remove the pale of improper influence and set
a decidedly more altruistic tone. Alternatively, the legislature could subject
manufacturers to the Board of Pharmacy Licensure and its related disciplinary
consequences under Chapter 4 of Title 26 of the Georgia Code, thereby holding
cannabis manufacturers to the same standards held to be sufficient for regulation
51

See Torres, supra note 4.
See Maggie Lee, Georgia Medical Cannabis Bill Finds More Critics, Macon Telegraph (Feb. 12, 2016,
2:21 pm), https://www.macon.com/news/politics-government/article60049216.html.
53
See Correction: Medical Marijuana Story, U.S. News (Feb. 14, 2018, 3:54 pm), https://www.usnews.
com/news/best-states/georgia/articles/2018-02-13/gov-deal-opposes-medical-marijuana-cultivation-in-georgia.
54
See Lee, supra note 52.
52
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of other privately-owned, commercial prescription-drug dispensaries around the
state. The legislature could also work more closely with prescribing physicians
to determine definitively the amount of cannabis needed for Georgia’s relatively
small patient population. If this effort could more accurately match supply to
demand, it might reduce the amount of cannabis available for unauthorized endusers.
No matter the extent to which the legislature utilizes H.B. 722 or the
commission’s recent recommendations, prospective manufacturers and their
legal counsel can be assured that all of the aforementioned considerations will
be taken into account and addressed, as they are crucial to building a consensus
proposal able to become law. The more that attorneys practicing in this emerging
area of law know regarding the development of these considerations, the more
likely they will be able to forecast for their clients the future landscape of
medical cannabis distribution in Georgia.
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